.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The evidence surrounding early antibiotic treatment in sepsis consistently supports prompt therapy for patients with suspected life-threatening infection, but also highlights the harms of unnecessary broad-spectrum exposure. Observational studies have linked delays in effective antibiotics with worse outcomes, while modern stewardship frameworks emphasize obtaining cultures rapidly, assessing the likelihood of bacterial infection and narrowing therapy when results become available. For general physicians, the challenge is operational: recognize sepsis early, establish source control and start appropriate empiric therapy without allowing “broad spectrum” to become synonymous with “better.” Local resistance data, prior microbiology, recent antibiotic exposure and healthcare-associated risk all matter. Reassessment at 24–72 hours is essential. At that point, de-escalation, discontinuation or narrowing should be considered when the clinical course and diagnostics support it. This approach addresses both the immediate patient's survival and the longer-term public-health threat of antimicrobial resistance, making it particularly relevant to APICON's infectious-disease and practical-medicine emphasis.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The evidence surrounding early antibiotic treatment in sepsis consistently supports prompt therapy for patients with suspected life-threatening infection, but also highlights the harms of unnecessary broad-spectrum exposure. Observational studies have linked delays in effective antibiotics with worse outcomes, while modern stewardship frameworks emphasize obtaining cultures rapidly, assessing the likelihood of bacterial infection and narrowing therapy when results become available. For general physicians, the challenge is operational: recognize sepsis early, establish source control and start appropriate empiric therapy without allowing “broad spectrum” to become synonymous with “better.” Local resistance data, prior microbiology, recent antibiotic exposure and healthcare-associated risk all matter. Reassessment at 24–72 hours is essential. At that point, de-escalation, discontinuation or narrowing should be considered when the clinical course and diagnostics support it. This approach addresses both the immediate patient's survival and the longer-term public-health threat of antimicrobial resistance, making it particularly relevant to APICON's infectious-disease and practical-medicine emphasis.
last month
Preclinical findings demonstrate that ginsenoside Ra1 preserves vascular integrity and attenuates multi-organ injury during sepsis by targeting non-muscle myosin heavy chain IIA (NMMHC IIA) and dampening TLR4/NF-κB/NLRP3 inflammatory signaling.
2 days back
An all-printed immunosensing microchip detects urinary sFlt-1 in just 10 minutes with 3.61 pg/mL sensitivity. By leveraging photonic bandgap engineering, this low-cost, cleanroom-free platform provides non-invasive preeclampsia screening, offering substantial benefits for point-of-care obstetric triage.
3 days back
Wearable ultrasound patches are transforming healthcare by shifting medicine from episodic evaluations to continuous monitoring. Discover how flexible acoustic transducers advance cardiovascular tracking, musculoskeletal imaging, neuromodulation, and on-demand closed-loop theranostics.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Last week
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Last week
